Biotech wins $3.9M grant for hep B work; Caprotec bumps B round to $7.2M; Napo sues Salix over collaboration pact;

 @FierceBiotech: Sanofi terminates $375M Metabolex diabetes deal. News | Follow @FierceBiotech 

 @JohnCFierce: I'm getting a sense that Big Pharma companies really are ready to walk away from deals they don't much like. It's not just talk. Follow @JohnCFierce

> Spring Bank Pharmaceuticals won a $3.9 million grant from the NIH for its work on an experimental hepatitis B therapy. Spring Bank release

> Berlin-based Caprotec bioanalytics has bumped its Series B haul to $7.2 million. The biotech has a facility in Burlington, MA. "This additional funding from LBBW Venture will allow us to further leverage caprotec's CCMS technology into additional markets as diagnostics and will put the company in a position to execute several large pharma partnerships at the same time." Says CEO Hubert Koster. Caprotec release

> Napo Pharmaceuticals has filed suit against Salix, saying the biotech breached its commitments under their collaboration pact on crofelemer. Salix fired back that Napo's claims "are without merit and the lawsuit is baseless." Napo release

> J&J says that its drug Stelara significantly outperformed a placebo in helping patients suffering from Crohn's disease. Report

Pharma News

@FiercePharma: Canada bars Biovail founder Melnyk from executive office. News | Follow @FiercePharma

> Chilean lawmakers weigh new drug regulatory agency. News

> Servier denies hiding risks of withdrawn diabetes drug. Story

> Pfizer's next top seller aces trials for new use. Article

> Sanofi looks to slow down on dealmaking. Report

Biotech IT News

> Scientists create 'schizophrenic' computer network to understand the disease. Item 

> Merge Healthcare part of "virtual" lab for cancer trial. Report 

> David Shaw goes from high finance to high-tech biotech simulations. Story 

> PerkinElmer acquires Geospiza, recognizes importance of genomic information. News 

> Open source drug discovery for the developing world. Article 

> Computational biology explains anti-cancer side-effect of HIV drug. Item 

Medical Device News

> Wright Medical replaces 3 more execs as USAO puts co. on notice. Report 

> U-Systems raises $6.5M in funding for breast screening application. Story 

> Samsung Medison aiming to become leading devicemaker by 2020. Item 

> Medtronic, Bayer Healthcare extend diabetes alliance. News 

> Boston Sci introduces smallest, thinnest high-energy CRT-Ds and ICDs. Article 

> FDA clears MicroPhage's test for drug-resistant Staph. Report 

> ITGI completes development of pericardium-covered stent. Story 

And Finally... A new study says that patients suffering from rheumatoid arthritis and lupus also run a significantly higher risk for atrial fibrillation and stroke. Story

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.